[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session .

2085 Eculizumab Is an Effective Treatment for Atypical Hemolytic Uremic Syndrome in Patients with or without Identified Genetic Complement Mutations or Complement Factor H Auto-Antibodies

Program: Oral and Poster Abstracts
Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism and Survival, Excluding Iron: Poster II
Sunday, December 9, 2012, 6:00 PM-8:00 PM
Hall B1-B2, Level 1, Building B (Georgia World Congress Center)

Samhar I. Al-Akash1*, Timothy H. J. Goodship, MD2*, Richard J. H. Smith, MD3*, Christophe M. Legendre, MD4*, Christoph Licht, MD5*, Petra Muus, MD, PhD6, Camille L. Bedrosian, MD7, Veronique Frémeaux-Bacchi, PhD8* and Chantal Loirat, MD9*

1Driscoll Children's Hospital, Corpus Christi, TX
2Newcastle University, Newcastle upon Tyne, England
3Deparment of Internal Medicine, University of Iowa, Iowa City, IA
4Universite Paris Descartes and Hôpital Necker, Paris, France
5Hospital for Sick Children, Toronto, ON, Canada
6Radboud University Medical Centre, Nijmegen, Netherlands
7Alexion Pharmaceuticals, Inc., Cheshire, CT
8Hôpital Européen Georges Pompidou, Parix, France
9Assistance Publique-Hôpitaux de Paris, Hôpital Robert-Debré, Paris, France

Introduction: Atypical hemolytic uremic syndrome (aHUS) is a rare chronic disorder characterized by persistent uncontrolled complement activation that results in life-threatening systemic thrombotic microangiopathy (TMA). In an estimated 50%–70% of patients (pts) with aHUS, uncontrolled complement activation can be attributed to identified genetic mutation(s) in complement regulatory factors and/or the presence of complement factor H auto-antibodies (CFH auto-Abs); newly identified complement mutations continue to be reported in the medical literature. For the 30%–50% of pts who currently have no identified genetic mutation/CFH auto-Abs, the overall risk of end-stage renal disease or death is high and similar to that observed in pts with known genetic mutation(s)/CFH auto-Abs, supporting the need for immediate management of disease in all aHUS pts regardless of mutation/CFH auto-Ab status. Eculizumab, an anti-C5 monoclonal antibody that inhibits terminal complement activation, is the only approved treatment for aHUS. Chronic eculizumab treatment has been proven to inhibit systemic TMA via terminal complement inhibition, improve renal function, and reduce or eliminate the need for plasma exchange/infusion (PE/PI) and dialysis. Furthermore, earlier eculizumab treatment has been associated with greater clinical improvement. The purpose of this analysis was to evaluate the relative efficacy of eculizumab in aHUS pts with or without identified genetic complement mutation(s)/CFH auto-Abs based on data from 3 clinical studies.

Methods: This report summarizes a subgroup analysis of efficacy outcomes based on the presence or absence of identified genetic mutation(s)/CFH auto-Abs in 3 aHUS studies: 2 controlled, prospective studies (pts aged ≥12 y), and 1 retrospective study (pts aged <18 y).

Results: Across the 3 studies, 24%–41% of pts had no identified genetic complement mutation or detectable CFH auto-Abs. The efficacy of eculizumab was similar regardless of mutation/CFH auto-Ab status (Table).

Conclusions: Across 3 studies investigating the efficacy of eculizumab treatment in aHUS pts, our analysis shows that improvements in hematologic, renal, and supportive care interventions (PE/PI, dialysis) outcomes were similar in pts with or without identified genetic complement mutation(s)/CFH auto-Abs. Given that (1) genetic testing often requires several months to complete, (2) uncontrolled complement activation places aHUS pts at risk of life-threatening systemic TMA events and organ damage, and (3) earlier intervention with eculizumab is associated with greater clinical improvement, we conclude that the results of this analysis provide a rationale for initiating eculizumab as first-line therapy at the time of clinical diagnosis of aHUS, without the availability of genetic testing results.

Table. Efficacy of eculizumab in pts with or without an identified genetic complement mutation and/or CFH auto-Abs

Parameter

Pts with Long Duration of Disease (Median Eculizumab Duration 114 Weeks)

(N=20)

Pts with Progressing TMA (Median Eculizumab Duration 100 Weeks)

(N=17)

Pediatric Pts (Retrospective Study)a

(N=17)

Identified
mutationb

n=13

No
identified
mutationc

n=7

Identified
mutationb

n=13

No
identified
mutation

n=4

Identified
mutation

n=10

No
identified
mutation

n=7

TMA event-free status,d n (%)

13 (100)

6 (86)

12 (92)

3 (75)

7 (70)

5 (71)

Platelet count 150×109/L, n (%)

12 (92)

6 (86)

12 (92)

3 (75)

10 (100)

6 (86)

Hematological normalization,f n (%)

12 (92)

6 (86)

12 (92)

3 (75)

4 (40)

3 (43)

Serum creatinine decrease ≥25%, n (%)

7 (54)

4 (57)

11 (85)

2 (50)

4 (40)

4 (57)

eGFR increase ≥15 mL/min/1.73 m2, n (%)

5 (38)

3 (43)

8 (62)

2 (50)

5 (50)

3 (43)

eGFR increase, mL/min/1.73 m2, mean (SE)

8.0 (2.1)g

2.0 (9.5)

37.7 (10.0)

35.7 (20.0)e

NA

NA

eGFR, estimated glomerular filtration rate; NA, not available; SE, standard error.
aVariable follow-up duration.
bIdentified genetic mutations includes CFH auto-Abs.

cA pt with a CFHR1-3 deletion has been included under no identified mutation for this analysis.
dNo decrease in platelet count of >25%, no PE/PI, and no new dialysis 12 consecutive weeks.
eData from pt who discontinued after 1 dose due to an exclusion criteria is not included.
fPlatelet count ≥150×109/L and lactate dehydrogenase ≤ upper limit of normal for 4 weeks.
gFor the 1 pt receiving transplant during study, post-transplant d
ata are excluded.

Disclosures: Goodship: Alexion Pharmaceuticals: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding, Speakers Bureau. Legendre: Alexion Pharmaceuticals: Speakers Bureau. Licht: Alexion Pharmaceuticals, Inc.: Consultancy, Honoraria, Research Funding. Muus: Alexion Pharmaceuticals. : Sat on advisory board of Alexion Pharmaceuticals. Other. Bedrosian: Alexion Pharmaceuticals: Employment, Equity Ownership. Loirat: Alexion Pharmaceuticals: Coordinator of Alexion trials of eculizumab in atypical HUS for France. Honoraria for conferences. Other.

*signifies non-member of ASH